Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences is a proteomics company that has built a detection platform designed to measure proteins at concentrations previously unattainable by existing tools. Founded in 2018 and based in Fremont, California, the company went public on NASDAQ in April 2026. Its core offering is the NULISA platform—a technology that uses antibody pairs and proximity ligation amplification to detect protein biomarkers in bodily fluids. The company sells this as a complete system: the ARGO HT instrument (a fully automated high-throughput analyzer), consumables (assay kits and reagents), and services through research labs and biopharmaceutical partners.

The company’s clients include contract research organizations, biopharmaceutical companies, academic institutions, and service labs working in immunology, oncology, neurology, and drug development. Revenue comes from three main streams: upfront instrument sales, ongoing consumable purchases, and services tied to protocol development and sample analysis. By the end of 2025, the company had placed over 100 ARGO HT systems globally and built relationships with more than 300 customers across 25 countries.

“NULISA breaks through the design limitations of existing proteomics tools, delivering ultra-high sensitivity, high specificity, flexible multiplex protein detection, broad dynamic range and seamless automation.”

The competitive strength lies in sensitivity: NULISA can detect proteins at extremely low concentrations where rivals hit detection floors. This matters because biomarkers often appear in minute quantities in blood or cerebrospinal fluid, and missing them can mean missing disease signals. The two-step capture and amplification design offers both speed and scale—the instrument can run hundreds of samples in parallel—making it practical for screening cohorts, not just individual research projects.

Alamar entered a market flooded with proteomics startups and established vendors, but its technical differentiation in sensitivity and throughput has earned early adoption. The 10-K filings and investor disclosures reflect investor appetite for precision medicine tools that sit upstream in the clinical workflow, between basic research and diagnostics. The company’s recent growth trajectory suggests sustained demand, though profitability and long-term market positioning depend on expanding adoption in drug development pipelines and eventual clinical diagnostics applications.